Genmab | GEN - Des Atouts





Des Atouts Changement Date
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Almirall EUR 2.34B 29.21M 2025-12
Amarin USD 645.76M 25.01M 2026-03
Amgen USD 92.5B 1.92B 2026-03
argenx SE USD 8.68B 1.51B 2025-12
AstraZeneca USD 114.02B 59M 2026-03
Bayer EUR 107.94B 3.4B 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Demant DKK 39.07B 6.43B 2025-12
Exelixis USD 2.59B 250.83M 2026-03
Fresenius Medical Care EUR 31.47B 465.26M 2026-03
Genmab DKK 12.87B 5.85B 2025-12
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
GN Store Nord DKK 28.56B 671M 2026-03
GRIFOLS EUR 20.08B 366M 2026-03
Hikma Pharmaceutical USD 5.67B 117M 2025-12
Insmed USD 2.08B 188.7M 2026-03
Lakefront Biotherapeutics EUR 3.37B 34.09M 2026-03
Lonza CHF 18.97B 164M 2025-12
Merck EUR 53.07B 1.54B 2026-03
Novartis USD 118.53B 7.58B 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sanofi EUR 128.02B 1.22B 2026-03
UCB EUR 18.16B 971M 2025-12